CompletedNCT02432703
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
Researchers compared JNJ-42165279 and placebo, tracking side effects to assess safety and tolerability in people with an anxiety condition.
Medication studyAges 18–64Multiple countries
Understand this study
What did researchers investigate?
Researchers compared JNJ-42165279 and placebo, tracking side effects to assess safety and tolerability in people with an anxiety condition.
Who was this study for?
Listed age limits: 18 years to 64 years.
- Listed locations
- La Jolla and 20 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: June 11, 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 150
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Australia, Canada
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT02432703
- Official title
Show the full official title
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Social Anxiety Disorder.
Recruitment & locations
CompletedLa Jolla, United States · Hartford, United States · Orlando, United States
18 more locations
- Chicago, United States
- Boston, United States
- Natick, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Allentown, United States
- Reading, United States
- Dallas, United States
- Salt Lake City, United States
- Adelaide, Australia
- Frankston, Australia
- Melbourne, Australia
- Perth, Australia
- Edmonton, Canada
- Hamilton, Canada
- Mississauga, Canada
- Toronto, Canada
Questions about this study
What did researchers investigate?
Researchers compared JNJ-42165279 and placebo, tracking side effects to assess safety and tolerability in people with an anxiety condition.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including JNJ-42165279 and Placebo.
Who was this study for?
Listed age limits: 18 years to 64 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder